We are live on
!
Find out more
DGM
Darwin Global Management Portfolio holdings
AUM
$3.76B
1-Year Est. Return
342.13%
This Fund
S&P 500
This Quarter
Est. Return
+47.31%
1 Year Est. Return
+342.13%
3 Year Est. Return
+2,581.87%
5 Year Est. Return
+47,632.22%
10 Year Est. Return
–
AUM
$3.76B
AUM Growth
-$10.4M
(-0.28%)
Cap. Flow
-$9.05M
Cap. Flow
% of AUM
-0.24%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
3
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$1.23B |
| 2 |
ABVX
Abivax
ABVX
|
+$17.3M |
| 3 |
BLTE
Belite Bio
BLTE
|
+$3.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$1.26B |
| 2 |
Roivant Sciences
ROIV
|
+$1.48M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$1.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
FG
CAM
AIP
AS
MHI
SWM
HAM
GKWIM
Darwin Global Management's Q2 2026 Portfolio in Review
As of Q2 2026, Darwin Global Management held 6 positions worth $3.76B, down 0.28% from $3.77B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Darwin Global Management's Q2 2026 filing shows 3 increased, 2 reduced and 1 closed positions. The largest sale was Insmed, an estimated $1.26B.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Darwin Global Management added most to Revolution Medicines in Q2 2026, an estimated $1.23B increase.
- Darwin Global Management's biggest Q2 2026 reduction was Insmed, cutting an estimated $1.26B.
- Darwin Global Management fully exited Dianthus Therapeutics in Q2 2026, selling an estimated $1.46M.
- Darwin Global Management's ten largest holdings make up 100% of its $3.76B portfolio in Q2 2026.
- Darwin Global Management opened 0 new positions and closed 1 in Q2 2026.
- Darwin Global Management's portfolio value fell 0.28% quarter-over-quarter to $3.76B.
Based on Darwin Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.